References
- Blinder V S, Roboz G J. Hematopoietic growth factors in myelodysplastic syndromes. Curr Hematol Rep 2003; 2: 453–458
- Hellstrom-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr Hematol Rep 2003; 2: 122–129
- Clavio M, Balleari E, Garrone A, Ballerini F, Varaldo R, Michelis G L, et al. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?. J Exp Clin Cancer Res 2005; 24: 5–16
- Negrin R S, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82: 737–743
- Hellstrom-Lindberg E, Birgegard G, Carlsson M, Carneskog J, Dahl I M, et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 1993; 11: 221–228
- Jadersten M, Montgomery S M, Dybedal I, Porwit- MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803–811
- Rigolin G M, Porta M D, Ciccone M, Bugli A M, Bragotti L Z, Mauro E, et al. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol 2004; 126: 501–507
- Geissler R G, Schulte P, Ganser A. Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes. Int J Hematol 1997; 65: 339–354
- Chuncharunee S, Intragumtornchai T, Chaimongkol B, Prayoonwiwat W, Leelasiri A, Lekhakula A, et al. Treatment of myelodysplastic syndrome with low-dose human granulocyte colony-stimulating factor: a multicenter study. Int J Hematol 2001; 74: 144–146
- Kaye J A. FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells 1998; 2: 207–223
- Ganser A, Lindemann A, Seipelt G, Ottmann O G, Herrmann F, Eder M, et al. Clinical effects of recombinant human interleukin-3. Am J Clin Oncol 1991; 1: S51–S63
- Ganser A, Seipelt G, Eder M, Geissler G, Ottmann O G, Hess U, et al. Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs. Semin Oncol 1992; 19: 95–101
- Nand S, Sosman J, Godwin J E, Fisher R I. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood 1994; 83: 357–360
- Gordon M S, Nemunaitis J, Hoffman R, Paquette R L, Rosenfeld C, Manfreda S, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066–3076
- Kizaki M, Miyakawa Y, Ikeda Y. Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome. Br J Haematol 2003; 122: 764–767
- Giles F J, Kantarjian H M, Cortes J E, Faderl S, Verstovsek S, Thomas D, et al. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 2005; 29: 649–652
- Tsimberidou A M, Giles F J, Khouri I, Bueso-Ramos C, Pilat S, Thomas D A, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the MD. Anderson Cancer Center experience. Ann Oncol 2005; 16: 139–145
- Montero A J, Estrov Z, Freireich E J, Khouri I F, Koller C A, Kurzrock R. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma 2006; 47: 2049–2054